Study identifier:ACE-ST-209
ClinicalTrials.gov identifier:NCT02586857
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)
Glioblastoma Multiforme
Phase 1/2
No
ACP-196
All
24
Interventional
n/a - n/a
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Jul 2024 by AcertaPharma
AcertaPharma
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Cohort 1 ACP-196 200 mg administered orally (PO) twice per day (BID) | Drug: ACP-196 Cohort 1: ACP-196 200 mg (PO) twice per day (BID) Cohort 2: ACP-196 400 mg (PO) once per day (QD). Other Name: Acalabrutinib. |
Experimental: Cohort 2 ACP-196 400mg administered orally (PO) once per day (QD). | Drug: ACP-196 Cohort 1: ACP-196 200 mg (PO) twice per day (BID) Cohort 2: ACP-196 400 mg (PO) once per day (QD). Other Name: Acalabrutinib. |